Roll-out of affordable malaria vaccine begins

What happened

Babies in the Ivory Coast and South Sudan will begin receiving doses of the world's first affordable malaria vaccine from today. R21, approved for children under three, costs around $4 a dose and is up to 79% effective at preventing the disease.

Who said what

"A malaria-free world is finally within sight," Adar Poonawalla, the chief executive of India-based manufacturer the Serum Institute, said to The Times. "It's been long awaited, but here we finally are," said Adrian Hill, the director of the Jenner Institute at Oxford University, who has been working on malaria vaccines for 30 years.

R21 has a "huge advantage" over the only other malaria jab, said The Times. RTS,S, developed by British drug-maker GlaxoSmithKline, is more than twice as expensive and manufacturing capacity is limited to six million doses a year, compared with 100 million for R21.

What next?

Fifteen African countries will have introduced the R21 vaccine by the end of the year, with another 15 due to follow. Trials for pregnant women will start in the coming weeks.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up